alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 23,676–23,700 of 27,380 studies, newest first · page 948 of 1096.

May 2005 7

  1. 2005-05-01

    MRI predictors of risk of incident Alzheimer disease: a longitudinal study

    ✓ Peer-reviewed Brain scans and imaging Neurology

    Key finding: In nondemented individuals, entorhinal cortex atrophy is associated with risk of Alzheimer disease. +2 more findings

    Full summary, score breakdown and related studies → Original source

  2. 2005-05-01

    High total cholesterol levels in late life associated with a reduced risk of dementia

    ✓ Peer-reviewed Prevention and risk Neurology

    Key finding: High cholesterol in late life was associated with decreased dementia risk, which is in contrast to previous studies suggesting high cholesterol in mid-life is a risk factor for later dementia. +4 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2005-05-01

    [The role of copper in the pathophysiology of Alzheimer's disease]

    ✓ Peer-reviewed Treatments Der Nervenarzt

    Key finding: APP is probably involved in the homeostasis of cellular copper (Cu) metabolism, because significantly changed Cu levels in the brain were found in AD patients as well as in mouse models. +1 more finding

    Full summary, score breakdown and related studies → Original source

  4. 2005-05-01

    Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results

    ✓ Peer-reviewed Treatments Archives of neurology

    Key finding: Atorvastatin treatment may be of some clinical benefit and could be established as an effective therapy for Alzheimer disease if the current findings are substantiated by a much larger multicenter trial. +2 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2005-05-01

    Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

    ✓ Peer-reviewed Treatments Neurology

    Key finding: Two hundred eighty-eight patients had paired scans (mean interval 10.9 months). +1 more finding

    Full summary, score breakdown and related studies → Original source

  6. 2005-05-01

    Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial

    ✓ Peer-reviewed Treatments Neurology

    Key finding: Following reports of meningoencephalitis (overall 18/300 [6%]), immunization was stopped after one (2 patients), two (274 patients), or three (24 patients) injections. +2 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2005-05-01

    APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study

    ✓ Peer-reviewed Genetics Neurology

    Key finding: This observational study provides further evidence that lipid-lowering agents are associated with decreased risk of dementia, whereas hyperlipidemia is associated with increased odds for non-Alzheimer-disease-type dementia. +4 more findings

    Full summary, score breakdown and related studies → Original source

April 2005 18

  1. 2005-04-29

    Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study

    ✓ Peer-reviewed Getting a diagnosis BMJ (Clinical research ed.)

    Key finding: Obesity in middle age increases the risk of future dementia independently of comorbid conditions. +2 more findings

    Full summary, score breakdown and related studies → Original source

  2. 2005-04-25

    Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications

    ✓ Peer-reviewed Disease mechanisms Annals of Neurology

    Key finding: Significant (p < 0.01) decreases occurred in the activities of the pyruvate dehydrogenase complex (-41%), isocitrate dehydrogenase (-27%), and the alpha-ketoglutarate dehydrogenase complex (-57%).

    Full summary, score breakdown and related studies → Original source

  3. 2005-04-25

    Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia

    ✓ Peer-reviewed Tau biomarkers Neuroscience letters

    Key finding: T-tau level was found significantly higher in groups of AD (t = 3.015, P < 0.01) and VD (t = 2.872, P < 0.01) than in controls. +4 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2005-04-24

    A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

    ✓ Peer-reviewed Cognitive tests and assessment Nature medicine

    Key finding: Serial PET scans showed significant (P < 0.05) increases in cortical 18-fluorodeoxyglucose after treatment.

    Full summary, score breakdown and related studies → Original source

  5. 2005-04-15

    Hypnotics should not be considered for the initial treatment of chronic insomnia. Con

    ✓ Peer-reviewed Health systems and care delivery Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

    Key finding: Analysis of the use of hypnotic medication versus CBT for insomnia using an established model for ethical medical decision making leads to the conclusion that hypnotics are not appropriate as the initial treatment in cases of chronic insomnia. +3 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2005-04-15

    Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment

    ✓ Peer-reviewed Biomarkers Neurobiology of aging

    Key finding: Glial HO-1 expression in the MCI temporal cortex and hippocampus was significantly greater than in the non-demented group and did not differ from AD values. +2 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2005-04-14

    Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo

    ✓ Peer-reviewed Inflammation and the immune system Science

    Microglial cells represent the immune system of the mammalian brain and therefore are critically involved in various injuries and diseases.

    Full summary, score breakdown and related studies → Original source

  8. 2005-04-14

    Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice

    ✓ Peer-reviewed Lewy body dementia The Journal of biological chemistry

    Key finding: Significantly, the reduction in mitochondrial complex V levels in the P301L tau mice revealed using proteomics was also confirmed as decreased in human P301L FTDP-17 (frontotemporal dementia with parkinsonism linked to chromosome 17) brains. +4 more findings

    Full summary, score breakdown and related studies → Original source

  9. 2005-04-13

    Vitamin E and donepezil for the treatment of mild cognitive impairment

    ✓ Peer-reviewed Mild cognitive impairment The New England journal of medicine

    Key finding: Vitamin E had no benefit in patients with mild cognitive impairment. +4 more findings

    Full summary, score breakdown and related studies → Original source

  10. 2005-04-11

    beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase

    ✓ Peer-reviewed Risk genes beyond APOE The Journal of biological chemistry

    Key finding: Much has been discovered on the properties of these proteases; however, regulatory mechanisms of enzyme-substrate interaction in neurons and their involvement in pathological changes are still not fully understood. +3 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2005-04-06

    Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation

    ✓ Peer-reviewed Inflammation and the immune system The Journal of biological chemistry

    Key finding: Current treatments for these diseases are not effective. +3 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2005-04-02

    Unified segmentation

    ✓ Peer-reviewed Brain scans and imaging NeuroImage

    Key finding: A probabilistic framework is presented that enables image registration, tissue classification, and bias correction to be combined within the same generative model. +3 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2005-04-01

    The cardiovascular continuum and renin–angiotensin–aldosterone system blockade

    ✓ Peer-reviewed Drug development Journal of Hypertension

    Key finding: Progressive tissue damage can result in morbidity from congestive heart failure, end-stage heart disease, nephrotic proteinuria and dementia and, eventually, death from cardio- or cerebrovascular causes. +1 more finding

    Full summary, score breakdown and related studies → Original source

  14. 2005-04-01

    Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings

    ✓ Peer-reviewed Digital health tools Journal of managed care pharmacy : JMCP

    Key finding: For the cohort of patients that remained on therapy > or =60 days, the mean time to treatment discontinuation was 331 days (95% confidence interval [CI], 307-355) for rivastigmine patients (n = 392) versus 337 days (95% CI, 322-352) for donepezil patients (n = 1288). +3 more findings

    Full summary, score breakdown and related studies → Original source

  15. 2005-04-01

    Early community-based service utilization and its effects on institutionalization in dementia caregiving

    ✓ Peer-reviewed Health systems and care delivery The Gerontologist

    Key finding: An analysis of interaction terms in the Cox regression model found that those individuals who utilized in-home help services earlier in their dementia caregiving careers were more likely to delay institutionalization.

    Full summary, score breakdown and related studies → Original source

  16. 2005-04-01

    Neurovascular mechanisms of Alzheimer's neurodegeneration

    ✓ Peer-reviewed Vascular contributions Trends in neurosciences

    Key finding: In contrast to traditional neuroncentric views of Alzheimer's disease (AD), recent findings indicate that neurovascular dysfunction contributes to cognitive decline and neurodegeneration in AD. +1 more finding

    Full summary, score breakdown and related studies → Original source

  17. 2005-04-01

    The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

    ✓ Peer-reviewed Treatments Current Alzheimer research

    Key finding: Recent phase 3 clinical trials have shown that memantine is effective in the treatment of both mild and moderate-to-severe Alzheimer's disease and possibly vascular dementia (multi-infarct dementia). +2 more findings

    Full summary, score breakdown and related studies → Original source

  18. 2005-04-01

    A potential role of the curry spice curcumin in Alzheimer's disease

    ✓ Peer-reviewed Treatments Current Alzheimer research

    Key finding: There is substantial in-vitro data indicating that curcumin has antioxidant, anti-inflammatory, and anti-amyloid activity. +4 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →